Search
User Profile
Change
Select your user profile

CoaguChek® INRange system

More control. More time in therapeutic range.
IVD For in vitro diagnostic use.
CoaguChek® INRange system
CoaguChek® INRange system

More control. More engaged patients. More time in therapeutic range.

CoaguChek INRange is the connected self-testing meter that enables your patients to test their NR whenever, wherever* - for confident control of their VKA therapy.

CoaguChek INRange
Do you have any questions?
Contact us

Connectivity

 

Built-in wireless, Bluetooth® technology allows you to be connected to your patients, who can now transmit their PT/INR results from their meter to you. This will help you to keep patients on track and in range–anytime, anywhere.

CoaguChek technology and quality have been recognised to facilitate VKA patient self-testing in a safe, accurate and reliable manner.1

 

More time in range

 

Patients who spend a high proportion of time (> 70%) in the therapeutic range achieve better clinical outcomes.2,3 Studies show that this can be achieved through self-testing using CoaguChek technology.1,4

 

More engaged patients

 

Patients who self-test are more engaged in their own care, test more often and spend more time in therapeutic range.4,5

 

Value of patient self-testing

 

Patient self-testing has been shown to result in more time spent in therapeutic range,6-8 fewer very high or very low INR values,8 fewer thromboembolic events,9-10 improved patient quality of life,11,12 and better treatment satisfaction11,13 as compared to usual care.

Related portfolios

CoaguChek INRange

The CoaguChek INRange system features

  • Results trend reporting: The CoaguChek INRange meter will let your patients know if their most recent result is higher or lower than their last result to help understand trends.

  • Bluetooth or USB connectivity: Connect the meter to a mobile app via Bluetooth or USB to quickly and easily send results to the healthcare professional. For more information about compatible software for data transfer with the CoaguChek INRange meter please contact your local Roche Diagnostics customer support.

  • Colour display: The colour display makes important information such as colour-coded results noticeable so that they are easy to read and understand.

  • Target range aware: Once you set up targets in your CoaguChek INRange, it will clearly let the patient know about results out of that range.

  • Commenting: The patient can enter up to six comments with each result to help them remember any past actions that may have affected the result.

  • Reminders and on-screen help: Reminders can be set up for important events such as when to test, take medication or next doctor's appointment. On-screen help provides text guidance throughout the test procedure.
How to use CoaguChek INRange

System components

  • CoaguChek INRange meter
  • CoaguChek XS Softclix lancing device -for single patient use only
  • CoaguChek Softclix lancets (bag of 10)
  • Carrying case
  • User's manual, Quick reference guide
  • USB cable, 4 x AAA batteries

 

Additional required components

 

  • CoaguChek XS PT Test PST strips (in a vial)
CoaguChek INRange
Doctor talking with patient

Coagulation monitoring

More efficiency in my care facility. More freedom for my patients

A variety of models exists for managing patients of VKA therapy.  Learn more about the benefits of point of care and patient self-testing and how we can support you in selecting the right model for you and your patients. 

You might be interested in

...
    ...

    *Do not use the meter at an altitude higher than 14,000 feet (4,300 meters).

    Abbreviations

    INR: International Normalized Ratio

    PT: Prothrombin time

    References

    1. Sharma, P., Scotland, G., Cruickshank, M., Tassie, E., Fraser, C., et al. (2015). Is self-monitoring an effective option for people receiving long-term vitamin K antagonist therapy? A systematic review and economic evaluation. BMJ Open 5:e007758
    2. Gallagher,A.M., Setakis, E., Plumb, J.M., Clemens, A., van Staa, T.P. (2011). Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost 106, 968–977
    3. Wan, Y., Heneghan, C., Perera, R., Roberts, N., Hollowell, J., et al. (2008). Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes 1, 84–91
    4. Ward A, Tompson A, Fitzmaurice D, Sutton S, PereraR., et al. (2015). Cohort study of Anticoagulation Self-Monitoring (CASM): a prospective study of its effectiveness in the community. Br J Gen Pract. 65(636):e428-437
    5. Heneghan C., Ward A., Perera R., et al. (2012). Self-monitoring of oral anticoagulation:systematic review and meta-analysis of individual patient data. Lancet 379:322-334
    6. Bereznicki, L.R.E., Jackson, S.L., Peterson, G.M. (2013). Supervised patient self-testing of warfarin therapy using an online system. J Med Internet Res 15, e138
    7. Christensen, H., Lauterlein, J.-J., Sørensen, P.D., Petersen, E.R.B., Madsen, et al. (2011). Home management of oral anticoagulation via telemedicine versus conventional hospital-based treatment. Telemed J E-Health Off J Am Telemed Assoc 17, 169–176
    8. Bussey, H.I., Bussey M., Bussey-Smith K.L., Frei, C.R. (2013). Evaluation of warfarin management with international normalized ratio self-testing and online remote monitoring and management plus low-dose vitamin k with genomic considerations: a pilot study. Pharmacotherapy 33, 1136–1146
    9. Heneghan, C., Ward, A., Perera, R., Bankhead, C., Fuller, A., et al. (2012). Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. Lancet 379, 322–334
    10. Heneghan, C., Alonso-Coello, P., Garcia-Alamino, J.M., Perera, R., Meats, E., Glasziou, P. (2006). Self-monitoring of oral anticoagulation: a systematic review and meta-analysis. Lancet 367, 404–411
    11. Matchar, D.B., Jacobson, A., Dolor, R., Edson, R., Uyeda, L., et al. (2010). Effect of home testing of international normalized ratio on clinical events. N Engl J Med 363, 1608–1620
    12. Salvador, C.H., Ruiz-Sanchez, A., González de Mingo, M.A., Carmona Rodríguez, M., Carrasco, et al. (2008). Evaluation of a telemedicine based service for the follow-up and monitoring of patients treated with oral anticoagulant therapy. EEE Trans Inf Technol Biomed 12, 696–706
    13. Gardiner, C., Williams, K., Mackie, I.J., Machin, S.J., Cohen, H. (2005). Patient self-testing is a reliable and acceptable alternative to laboratory INR monitoring. Br J Haematol 128, 242–247
    Contact Us

    Overview

    Ordering Information

    Technical specifications

    Technical specifications

    Detection system
     

    Amperometric (electrochemical) determination of the PT time after activation of the coagulation with human recombinant thromboplastin

     

    User interface
     

    Intuitive user interface with color display, on/off, enter, back and up/down button

     

    Sample application
     

    Outside the meter top-and 2 sides: left or right,-dosing options

    Temperature
     

    + 15° C to + 32° C (59° F to 90° F)

     

    Humidity
     

    10 -85%

     

    Maximum altitude
     

    4300 m (14,000 ft)

     

    Placement
     

    -First option: Operate the monitor on a level surface, free of vibrations

    -Second option: Hold the monitor in your hand, so that it is roughly horizontal

     

    Measuring range INR
     

    0.8 -8.0

     

    Interface
     

    USB (Type B) and Bluetooth

     

    Power
     

    Battery -Four 1.5v AAA alkali-manganese batteries

    # of tests per set of batteries

    Up to 60 tests or 1 year

     

    Size
     

    145 x 75 x 30 mm

     

    Weight
     

    135 g (without batteries)

     

    Memory
     

    400 Test Results

     

    Auto power off
     

    Auto off after 2 minutes of inactivity

    Sample type
     

    Fresh capillary whole blood

     

    Sample size
     

    ≥ 8 μl

     

    Interferences
     

    Refer to the test-strip package insert

    ISI
     

    Approx. 1.0

     

    Sensitivity to heparin
     

    Not at therapeutic levels, up to 0.8 I.U/ml for UFH and to 2 anti-Xa U/ml for LMWH

     

    Quality control
     

    On each strip, through the same channel as the blood passes

     

    Stability
     

    21 months from production (+ 2° C to + 30° C)

     

    Colour

    Display of target range

    Technical Documents

    multilangimg
       
    Document repository
    error errorMessage
    Sorry, we couldn't find the content you are looking for
    Please try again later

    Related products

    ...
      ...